12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

ViraferonPeg peginterferon alfa-2b regulatory update

The U.K.'s NICE issued final guidance recommending the use of Pegasys peginterferon alfa-2a from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) and ViraferonPeg peginterferon alfa-2b from Merck both in combination with ribavirin to treat chronic HCV infection in children. The guidance...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >